Your browser doesn't support javascript.
loading
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Pereira, Bernard; Chin, Suet-Feung; Rueda, Oscar M; Vollan, Hans-Kristian Moen; Provenzano, Elena; Bardwell, Helen A; Pugh, Michelle; Jones, Linda; Russell, Roslin; Sammut, Stephen-John; Tsui, Dana W Y; Liu, Bin; Dawson, Sarah-Jane; Abraham, Jean; Northen, Helen; Peden, John F; Mukherjee, Abhik; Turashvili, Gulisa; Green, Andrew R; McKinney, Steve; Oloumi, Arusha; Shah, Sohrab; Rosenfeld, Nitzan; Murphy, Leigh; Bentley, David R; Ellis, Ian O; Purushotham, Arnie; Pinder, Sarah E; Børresen-Dale, Anne-Lise; Earl, Helena M; Pharoah, Paul D; Ross, Mark T; Aparicio, Samuel; Caldas, Carlos.
Afiliação
  • Pereira B; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Chin SF; Department of Oncology, University of Cambridge, Cambridge CB2 2QQ, UK.
  • Rueda OM; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Vollan HK; Department of Oncology, University of Cambridge, Cambridge CB2 2QQ, UK.
  • Provenzano E; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Bardwell HA; Department of Oncology, University of Cambridge, Cambridge CB2 2QQ, UK.
  • Pugh M; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, Oslo 0310, Norway.
  • Jones L; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo 0318, Norway.
  • Russell R; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK.
  • Sammut SJ; Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS, Hills Road, Cambridge CB2 0QQ, UK.
  • Tsui DW; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Liu B; Inivata, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  • Dawson SJ; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK.
  • Abraham J; Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS, Hills Road, Cambridge CB2 0QQ, UK.
  • Northen H; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Peden JF; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Mukherjee A; Department of Oncology, University of Cambridge, Cambridge CB2 2QQ, UK.
  • Turashvili G; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Green AR; Department of Oncology, University of Cambridge, Cambridge CB2 2QQ, UK.
  • McKinney S; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Oloumi A; Peter MacCallum Cancer Centre, Melbourne, Victoria 3002, Australia.
  • Shah S; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK.
  • Rosenfeld N; Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS, Hills Road, Cambridge CB2 0QQ, UK.
  • Murphy L; Illumina, Chesterford Research Park, Little Chesterford, Essex CB10 1XL, UK.
  • Bentley DR; Illumina, Chesterford Research Park, Little Chesterford, Essex CB10 1XL, UK.
  • Ellis IO; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham NG5 1PB, UK.
  • Purushotham A; Department of Pathology and Molecular Medicine, Queen's University/Kingston General Hospital, 76 Stuart Street, Kingston, Ontario, Canada K7L 2V7.
  • Pinder SE; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham NG5 1PB, UK.
  • Børresen-Dale AL; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3.
  • Earl HM; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3.
  • Pharoah PD; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3.
  • Ross MT; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
  • Aparicio S; Research Institute in Oncology and Hematology, 675 McDermot Avenue, Winnipeg, Mannitoba, Canada R3E 0V9.
  • Caldas C; Illumina, Chesterford Research Park, Little Chesterford, Essex CB10 1XL, UK.
Nat Commun ; 7: 11479, 2016 05 10.
Article em En | MEDLINE | ID: mdl-27161491
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions. Associations between PIK3CA mutations and reduced survival are identified in three subgroups of ER-positive cancer (defined by amplification of 17q23, 11q13-14 or 8q24). High levels of intra-tumour heterogeneity are in general associated with a worse outcome, but highly aggressive tumours with 11q13-14 amplification have low levels of intra-tumour heterogeneity. These results emphasize the importance of genome-based stratification of breast cancer, and have important implications for designing therapeutic strategies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Nat Commun Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Nat Commun Ano de publicação: 2016 Tipo de documento: Article